Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 51 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.
Ma S, Suchomel J, Yanez E, Yost E, Liang X, Zhu R, Le H, Siebers N, Joas L, Morley R, Royer-Joo S, Pirzkall A, Salphati L, Ware JA, Morrissey KM
Br J Clin Pharmacol, 85(8):1751-1760, 14 Jun 2019
Cited by: 7 articles | PMID: 30973970 | PMCID: PMC6624388
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.
Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, He L, Morley R, Fassò M, Pirzkall A, Patel H, O'Hear C, Ferrara D
JAMA Ophthalmol, 137(1):96-100, 01 Jan 2019
Cited by: 8 articles | PMID: 30383154 | PMCID: PMC6439799
Add to export list Free full text in Europe PMC
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, [...] Davis SL
Clin Cancer Res, 25(11):3220-3228, 15 Feb 2019
Cited by: 134 articles | PMID: 30770348 | PMCID: PMC7980952
Add to export list Free full text in Europe PMC
ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)
Shih K, Schiff D, Kim L, Battiste J, Campian J, Puduvalli V, Wen P, Cloughesy T, van den Bent M, Pirzkall A, Wood K, Wei R, Du B, Mu S, Ramakrishnan V, Walbert T
Neuro Oncol, 20(suppl 6):vi17-vi18, 01 Nov 2018
Cited by: 0 articles | PMCID: PMC6216180
Add to export list Free full text in Europe PMC
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, [...] Khleif SN
J Immunother Cancer, 6(1):61, 20 Jun 2018
Cited by: 66 articles | PMID: 29921320 | PMCID: PMC6009946
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Bartolomeo MD, Bridgewater J, Coveler AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, [...] Tabernero J
Clin Cancer Res, 24(10):2276-2284, 05 Mar 2018
Cited by: 30 articles | PMID: 29506988
Add to export list
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J
Oncologist, 22(9):1024-e89, 07 Jun 2017
Cited by: 13 articles | PMID: 28592615 | PMCID: PMC5599193
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB
Front Oncol, 6:232, 31 Oct 2016
Cited by: 55 articles | PMID: 27843803 | PMCID: PMC5086582
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM
Cancer, 122(24):3803-3811, 15 Aug 2016
Cited by: 25 articles | PMID: 27525588
Add to export list
Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.
Fredrickson J, Serkova NJ, Wyatt SK, Carano RA, Pirzkall A, Rhee I, Rosen LS, Bessudo A, Weekes C, de Crespigny A
Magn Reson Med, 77(2):814-825, 26 Feb 2016
Cited by: 11 articles | PMID: 26918893 | PMCID: PMC5677523
Add to export list Free full text in Europe PMC
Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.
Qu X, Sandmann T, Frierson H, Fu L, Fuentes E, Walter K, Okrah K, Rumpel C, Moskaluk C, Lu S, Wang Y, Bourgon R, Penuel E, Pirzkall A, Amler L, Lackner MR, Tabernero J, Hampton GM, Kabbarah O
Oncogene, 35(50):6403-6415, 06 Jun 2016
Cited by: 45 articles | PMID: 27270421 | PMCID: PMC5161754
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J
Clin Cancer Res, 21(11):2462-2470, 01 Jun 2015
Cited by: 32 articles | PMID: 26034219 | PMCID: PMC5705193
Add to export list Free full text in Europe PMC
Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
Spahn J, Peng J, Lorenzana E, Kan D, Hunsaker T, Segal E, Mautino M, Brincks E, Pirzkall A, Kelley S, Mahrus S, Liu L, Dale S, Quiason C, Jones E, Liu Y, Latham S, Salphati L, DeMent K, [...] Hatzivassiliou G
J Immunother Cancer, 3(suppl 2):P303-P303, 01 Jan 2015
Cited by: 2 articles | PMCID: PMC4649373
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Hughes B, Mileshkin L, Townley P, Gitlitz B, Eaton K, Mitchell P, Hicks R, Wood K, Amler L, Fine BM, Loecke D, Pirzkall A
Oncologist, 19(2):175-176, 23 Jan 2014
Cited by: 15 articles | PMID: 24457379 | PMCID: PMC3926793
Add to export list Free full text in Europe PMC
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.
Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, Do A, Fu L, Xiao Y, Raja R, Jiang B, Malekafzali A, Stern H, Settleman J, Wilson TR, Hampton GM, Yauch RL, Pirzkall A, Amler LC
PLoS One, 8(2):e56765, 28 Feb 2013
Cited by: 40 articles | PMID: 23468880 | PMCID: PMC3586092
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR
Clin Cancer Res, 18(8):2391-2401, 05 Apr 2012
Cited by: 269 articles | PMID: 22492982
Add to export list
Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.
Ozturk-Isik E, Pirzkall A, Lamborn KR, Cha S, Chang SM, Nelson SJ
Transl Oncol, 5(1):10-18, 01 Feb 2012
Cited by: 7 articles | PMID: 22348171 | PMCID: PMC3281410
Add to export list Free full text in Europe PMC
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM
Clin Cancer Res, 17(10):3304-3315, 01 Mar 2011
Cited by: 78 articles | PMID: 21364032
Add to export list
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Binns DS, Pirzkall A, Yu W, Callahan J, Mileshkin L, Conti P, Scott AM, Macfarlane D, Fine BM, Hicks RJ, OSI3926g Study Team
Eur J Nucl Med Mol Imaging, 38(4):642-650, 05 Jan 2011
Cited by: 20 articles | PMID: 21207024
Add to export list
Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.
Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ
Neuro Oncol, 12(11):1152-1161, 20 Jul 2010
Cited by: 29 articles | PMID: 20647244 | PMCID: PMC3098023
Add to export list Free full text in Europe PMC
Molecular biomarker analyses using circulating tumor cells.
Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR
PLoS One, 5(9):e12517, 08 Sep 2010
Cited by: 170 articles | PMID: 20838621 | PMCID: PMC2935889
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.
Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ
Neuro Oncol, 11(6):842-852, 01 Dec 2009
Cited by: 72 articles | PMID: 19229057 | PMCID: PMC2802404
Add to export list Free full text in Europe PMC
Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.
Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ
J Neurooncol, 91(3):337-351, 15 Nov 2008
Cited by: 66 articles | PMID: 19009235 | PMCID: PMC3022444
Add to export list Free full text in Europe PMC
Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.
Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ
J Neurooncol, 91(1):69-81, 23 Sep 2008
Cited by: 94 articles | PMID: 18810326 | PMCID: PMC3022437
Add to export list Free full text in Europe PMC
Abstracts for the Twelfth Annual Meeting of the Society for Neuro-Oncology: November 15–18, 2007
Carson-Walter E, Liu Y, Winans B, Shue E, Walter K, Millard M, Müschen M, Erdreich-Epstein A, McFarland B, Stewart J, Nordal R, Davidson D, Henkin J, Gladson C, Guccione S, Jang T, Yang Y, Cao H, Haddix T, [...] Walker D
Neuro Oncol, 9(4):467-602, 01 Oct 2007
Cited by: 0 articles | PMCID: PMC1994106
Add to export list Free full text in Europe PMC

1-25 of 51 results

1 2 3

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.

Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.

High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.

Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Molecular biomarker analyses using circulating tumor cells.

Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Abstracts for the Twelfth Annual Meeting of the Society for Neuro-Oncology: November 15–18, 2007

Partnerships & funding